© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The premier platform not only for the presentation of new science, but also for unique networking opportunities.
A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.
The targeted therapy shrank tumors in more than half of people with previously treated non-small-cell lung cancer.
In recent years, deaths from non-small cell lung cancer (NSCLC) have decreased even faster than the decrease in NSCLC incidence.
These are the latest cancer treatments approved by the FDA.
Data from a large COVID-19 and cancer registry also showed that hydroxychloroquine plus azithromycin is associated with higher mortality.
Ramucirumab slowed disease progression more than a placebo when added to erlotinib.
Here’s a list of the approved drugs to treat lung cancer. Click on any of the medications for more info on dosing, side effects and d...
Study showed 74% overall response rate for people who used brigatinib as their first ALK inhibitor.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
